Mitsubishi Tanabe expands collaboration with US giant

6 February 2017

Japanese drug major Mitsubishi Tanabe Pharma (TYO: 4508) has announced the strengthening of its collaboration with Janssen, part of US healthcare giant Johnson & Johnson (NYSE: JNJ).

The companies have signed a co-promotion agreement for Stelara (ustekinumab) for an indication of Crohn’s disease for which Janssen has filed an application in Japan. Should that be approved, Janssen will distribute the drug while both firms will promote the product.

Since 2002, Mitsubishi Tanabe has distributed an intravenous injection formulation of Janssen’s big-selling inflammatory diseases drug Remicade (infliximab), to which Stelara has a different mechanism of action.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK